Design, synthesis and antimicrobial evaluation of novel benzimidazole-incorporated sulfonamide analogues

Zhang, Huizhen; He, Shunping; Peng, Yanjun; Zhang, Haijuan; Goodla, Lavanya; Tangadanchu, Vijai Kumar Reddy; Gan, Lin-Ling; Zhou, Cheng‐He

doi:10.1016/j.ejmech.2017.04.077

Cited by 100 publications

(28 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2) showed good antibacterial activity against B. typhi with MIC values 4 mg/mL. Compound 108 showed eight folds higher activity (MIC ¼ 4 mg/mL) than standard Chloromycin against B. typhi [59].…”

Section: Antimicrobial Agentsmentioning

confidence: 99%

Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review

Zhao

Rakesh

Ravidar

et al. 2019

European Journal of Medicinal Chemistry

449

183

View full text Add to dashboard Cite

a b s t r a c tSulfur (S VI ) based moieties, especially, the sulfonyl or sulfonamide based analogues have showed a variety of pharmacological properties, and its derivatives propose a high degree of structural diversity that has established useful for the finding of new therapeutic agents. The developments of new less toxic, low cost and highly active sulfonamides containing analogues are hot research topics in medicinal chemistry. Currently, more than 150 FDA approved Sulfur (S VI )-based drugs are available in the market, and they are widely used to treat various types of diseases with therapeutic power. This comprehensive review highlights the recent developments of sulfonyl or sulfonamides based compounds in huge range of therapeutic applications such as antimicrobial, anti-inflammatory, antiviral, anticonvulsant, antitubercular, antidiabetic, antileishmanial, carbonic anhydrase, antimalarial, anticancer and other medicinal agents. We believe that, this review article is useful to inspire new ideas for structural design and developments of less toxic and powerful Sulfur (S VI ) based drugs against the numerous death-causing diseases.

show abstract

Section: Antimicrobial Agentsmentioning

confidence: 99%

Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review

Zhao

Rakesh

Ravidar

et al. 2019

European Journal of Medicinal Chemistry

449

183

View full text Add to dashboard Cite

show abstract

“…This can be onerous given that the proteins which interact with and modify this macromolecule have retained many key features and commonalities as they have evolved in different species. For TB, which requires lengthy treatment, the need to avoid toxicity in the human host presents an additional major challenge, and one which is likely to exclude drugs which target DNA directly, such as DNA intercalating agents (Zhang et al, 2017 ), and inducers of replication stress in mammalian cells (i.e., anticancer compounds). Instead, antitubercular chemotherapies need to be designed to exploit specific nuances of, and vulnerabilities within, the complement of mycobacterial DNA replication and repair proteins (Mizrahi and Huberts, 1996 ; Rock et al, 2015 ).…”

Section: The Mycobacterial Dna Replication Machinerymentioning

confidence: 99%

Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis

Reiche

Warner

Mizrahi

2017

Front. Mol. Biosci.

View full text Add to dashboard Cite

Mycobacterium tuberculosis is the etiological agent of tuberculosis (TB), an infectious disease which results in approximately 10 million incident cases and 1.4 million deaths globally each year, making it the leading cause of mortality from infection. An effective frontline combination chemotherapy exists for TB; however, this regimen requires the administration of four drugs in a 2 month long intensive phase followed by a continuation phase of a further 4 months with two of the original drugs, and is only effective for the treatment of drug-sensitive TB. The emergence and global spread of multidrug-resistant (MDR) as well as extensively drug-resistant (XDR) strains of M. tuberculosis, and the complications posed by co-infection with the human immunodeficiency virus (HIV) and other co-morbidities such as diabetes, have prompted urgent efforts to develop shorter regimens comprising new compounds with novel mechanisms of action. This demands that researchers re-visit cellular pathways and functions that are essential to M. tuberculosis survival and replication in the host but which are inadequately represented amongst the targets of current anti-mycobacterial agents. Here, we consider the DNA replication and repair machinery as a source of new targets for anti-TB drug development. Like most bacteria, M. tuberculosis encodes a complex array of proteins which ensure faithful and accurate replication and repair of the chromosomal DNA. Many of these are essential; so, too, are enzymes in the ancillary pathways of nucleotide biosynthesis, salvage, and re-cycling, suggesting the potential to inhibit replication and repair functions at multiple stages. To this end, we provide an update on the state of chemotherapeutic inhibition of DNA synthesis and related pathways in M. tuberculosis. Given the established links between genotoxicity and mutagenesis, we also consider the potential implications of targeting DNA metabolic pathways implicated in the development of drug resistance in M. tuberculosis, an organism which is unusual in relying exclusively on de novo mutations and chromosomal rearrangements for evolution, including the acquisition of drug resistance. In that context, we conclude by discussing the feasibility of targeting mutagenic pathways in an ancillary, “anti-evolution” strategy aimed at protecting existing and future TB drugs.

show abstract

“…Sulfonamides and indazoles are important building blocks for pharmaceuticals and bioactive compounds. For example, ionidamine is an anticancer drug; YC‐1 is reported to exhibit anticancer activity; YD‐3 is an angiogenic drug; and WXL‐1 is a potent antimicrobial agent, newbouldine and neuro‐transmitter inhibitors (Figure ) …”

Section: Introductionmentioning

confidence: 99%

Copper‐catalyzed C‐N coupling reaction of tosylhydrazones

Jiang

et al. 2018

Applied Organom Chemis

View full text Add to dashboard Cite

Tosylhydrazones are a kind of labile and highly reactive compounds, which are apt to be transformed into reactive diazo compounds and then into extremely reactive carbenes under the basic condition. In order to fulfil the valuable C‐N coupling reaction, diaryliodonium salts are evaluated and prove to be a class of efficient electrophiles. The reaction with ligand‐free copper salt as catalyst shows a wide range of substrate scope. A plausible mechanism is proposed.

show abstract

Design, synthesis and antimicrobial evaluation of novel benzimidazole-incorporated sulfonamide analogues

Cited by 100 publications

References 48 publications

Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review

Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review

Targeting DNA Replication and Repair for the Development of Novel Therapeutics against Tuberculosis

Copper‐catalyzed C‐N coupling reaction of tosylhydrazones

Contact Info

Product

Resources

About